FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats

FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats

Source: 
Xconomy
snippet: 

An Alkermes antipsychotic treatment designed to offer the benefits of a commonly prescribed medicine, but without the weight gain side effect, won the backing of an FDA advisory committee on Friday. But even some of the panel members who supported the drug qualified their votes, expressing concern about what the drug could mean for patients taking opioid painkillers.